KaydedilenlerDerginizi ekleyin

Dergiler / Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi / 2026 / Volume: 21 Issue: 1

Effects of Trans-Cinnamaldehyde on Epithelial-Mesenchymal Markers in Prostate Cancer

Mehmet Balaban(SULEYMAN DEMIREL UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0009-0006-3701-984X
Zeynep Akpınar0000-0001-9547-3967
Nilgün Gürbüz(SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-4476-5593
Sayfa
—
Yayın Tarihi
2026-05-28
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These results underscore its therapeutic potential, warranting further in vivo and clinical investigations to fully assess efficacy and safety.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Advanced-stage prostate cancer is associated with low survival rates and high metastatic potential, often driven by epithelial–mesenchymal transition (EMT).
📊
Temel Bulgular & Veri:Cells were treated with 10–40 µM CA for 24 and 48 hours, and cell viability was assessed using the MTT assay to identify effective concentrations.
💡
Sonuç & Katkı:These results underscore its therapeutic potential, warranting further in vivo and clinical investigations to fully assess efficacy and safety.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Prostate Cancer · LNCaP · Cinnamaldehyde

Abstract

Advanced-stage prostate cancer is associated with low survival rates and high metastatic potential, often driven by epithelial–mesenchymal transition (EMT). Current therapeutic options remain limited, encouraging the exploration of natural compounds with anticancer potential. Cinnamaldehyde (CA), a bioactive compound derived from Cinnamomum bark, was investigated for its effects on EMT markers in LNCaP prostate cancer cells. Cells were treated with 10–40 µM CA for 24 and 48 hours, and cell viability was assessed using the MTT assay to identify effective concentrations. Expression levels of EMT-related genes such as E-cadherin, Claudin, ZEB-1, Vimentin and MMP-2 were analyzed via RT-PCR. CA reduced prostate cancer cell viability at 20–30 µM and modulated EMT, as evidenced by decreased mesenchymal markers (ZEB-1, MMP-2, Vimentin) and increased epithelial markers (E-cadherin, Claudin). These results underscore its therapeutic potential, warranting further in vivo and clinical investigations to fully assess efficacy and safety.

🔖

Bu Makaleye Atıf Yap

Balaban, M., Akpınar, Z., Gürbüz, N. (2026). Effects of Trans-Cinnamaldehyde on Epithelial-Mesenchymal Markers in Prostate Cancer. Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi, Volume: 21 Issue: 1. https://doi.org/10.29233/sdufeffd.1790466

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (41)

  1. S. Wasim, S. Y. Lee and J. Kim, “Complexities of Prostate Cancer”, International Journal of Molecular Sciences, 23(22), 14257, 2022.
  2. R. L. Siegel, K. D. Miller and A. Jemal, “Cancer Statistics, 2018”, CA Cancer Journal for Clinicians, 68(1), 7–30, 2018.
  3. R. B. Berish, A. N. Ali, P.G. Telmer, J. A. Ronald and H. S. Leong, “Translational Models of Prostate Cancer Bone Metastasis”, Nature Reviews Urology, 15(7), 403–421, 2018.
  4. M. Sekhoacha, K. Riet, P. Motloung, L. Gumenku, A. Adegoke and S. Mashele, “Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches”, Molecules, 27(17), 5730, 2022.
  5. A. W. Lambert, D. R. Pattabiraman and R. A. Weinberg, “Emerging Biological Principles of Metastasis”, Cell, 168(4), 670–691, 2017.
  6. C. Bach, S. Pisipati, D. Daneshwar, M. Wright, E. Rowe and D. Gillatt, “The Status of Surgery in the Management of High-Risk Prostate Cancer”, Nature Reviews Urology, 11(6), 342–351, 2014.
  7. K. Desai, J. M. McManus, N. Sharifi, “Hormonal Therapy for Prostate Cancer”, Endocrine Reviews, 42(3), 354–373, 2021.
  8. S. Kakkat, P. Pramanik, S. Singh, A. P. Singh, C. Sarkar and D. Chakroborty, “Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections”, International Journal of Molecular Sciences, 24(8), 6984, 2023.
  9. I. M. da Fonseca Pedroso, M. L. S. Siqueira, T. A. B. P. de Sousa Santos, K. de Paula Barbosa, E. A. N. de Lima and A. C. R. I. Sampaio, “Conservative Treatment of Sexual Dysfunction among Men Undergoing Prostate Cancer Treatment: A Systematic Review”, Sexual Medicine Reviews, 12(4), 710–719, 2024.
  10. K. Fukata, H. Kawamura, N. Kubo, T. Kanai, M. Torikoshi, T. Nakano, “Retrospective Comparison of Rectal Toxicity Between Carbon-Ion Radiotherapy and Intensity-Modulated Radiation Therapy Based on Treatment Plan, Normal Tissue Complication Probability Model, and Clinical Outcomes in Prostate Cancer”, Physica Medica, 90, 6–12, 2021.
  11. B.A. Cowan, K. Olivier, B. Tombal and J. S. Wefel, “Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes”, Advances in Therapy, 41(2), 476–491, 2024.
  12. T. Kulasegaran and N. Oliveira, “Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management”, Current Treatment Options in Oncology, 25(7), 914–931, 2024.
  13. W. K. Oh, P. W. Kantoff, V. Weinberg, G. Jones, B. I. Rini and M. K. Derynck, “Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer”, Journal of Clinical Oncology, 22(18), 3705–3712, 2004.
  14. N. B. Kumar, J. Pow-Sang, K. M. Egan, P. E. Spiess, S. Dickinson and R. Salup, “Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention”, Cancer Prevention Research, 8(10), 879–887, 2015.
  15. C. J. Paller, A. Pantuck and M. A. Carducci, “A Review of Pomegranate in Prostate Cancer”, Prostate Cancer and Prostatic Diseases, 20(3), 265–270, 2017.
  16. Y. H. Choi, D. H. Han, S. Kim, M. Kim, H. H. Sung and H. G. Jeon, “A Randomized, Double‐Blind, Placebo-Controlled Trial to Evaluate the Role of Curcumin in Prostate Cancer Patients with Intermittent Androgen Deprivation”, Prostate, 79(6), 614–621, 2019.
  17. E. Zhuang, E. Uchio, M. Lilly, X. Zi and J. P. Fruehauf, “A Phase II Study of Docetaxel plus Lycopene in Metastatic Castrate Resistant Prostate Cancer”, Biomedicine and Pharmacotherapy, 143, 112226, 2021.
  18. J. J. Alumkal, R. Slottke, J. Schwartzman, G. Cherala, M Munar and J. N. Graff, “A Phase II Study of Sulforaphane-Rich Broccoli Sprout Extracts in Men with Recurrent Prostate Cancer”, Investigational New Drugs, 33(2), 480–489, 2015.
  19. F. H. Sarkar and Y. Li, “Indole-3-Carbinol and Prostate Cancer”, Journal of Nutrition, 134(12), 3493S–3498S, 2004.
  20. W. Demark-Wahnefried, T. J. Polascik, S. L. George, B. R. Switzer, J F. Madden and M.T. Ruffin, “Flaxseed Supplementation (Not Dietary Fat Restriction) Reduces Prostate Cancer Proliferation Rates in Men Presurgery”, Cancer Epidemiology, Biomarkers and Prevention, 17(12), 3577–3587, 2008.
  21. J. Peng, X. Song, W. Yu, Y. Pan, Y. Zhang and H. Jian, “The Role and Mechanism of Cinnamaldehyde in Cancer”, Journal of Food and Drug Analysis, 32(2), 146–160, 2024.
  22. Y. Olayiwola and L. Gollahon, “Natural Compounds and Breast Cancer: Chemo-Preventive and Therapeutic Capabilities of Chlorogenic Acid and Cinnamaldehyde”, Pharmaceuticals, 17(3), 361, 2024.
  23. A. Nile, J. Shin, J. Shin, G. S. Park, S. Lee and J. H. Lee, “Cinnamaldehyde-Rich Cinnamon Extract Induces Cell Death in Colon Cancer Cell Lines HCT 116 and HT-29”, International Journal of Molecular Sciences, 24(9), 8191, 2023.
  24. Y. Wang, Y. Li, L. Wang, B. Chen, M. Zhu and C. Ma, “Cinnamaldehyde Suppressed EGF-Induced EMT Process and Inhibits Ovarian Cancer Progression Through PI3K/AKT Pathway”, Frontiers in Pharmacology, 13, 2022.
  25. Y. Geng, S. Yang, Z. Liu, S. Wang and P. Ge, “Cinnamaldehyde Regulates the Migration and Apoptosis of Gastric Cancer Cells by Inhibiting the Jak2/Stat3 Pathway”, Digestive Diseases and Sciences, 69(8), 2875–2882, 2024.
  26. Z. Aminzadeh, N. Ziamajidi and R. Abbasalipourkabir, “Anticancer Effects of Cinnamaldehyde Through Inhibition of ErbB2/HSF1/LDHA Pathway in 5637 Cell Line of Bladder Cancer”, Anticancer Agents in Medicinal Chemistry, 22(6), 1139–1148, 2022.
  27. S. Banerjee and S. Banerjee, “Anticancer Potential and Molecular Mechanisms of Cinnamaldehyde and Its Congeners Present in the Cinnamon Plant”, Physiologia, 3(2), 173–207, 2023.
  28. Y. Liu, T. An, D. Wan, B. Yu, Y. Fan and X. Pei, “Targets and Mechanism Used by Cinnamaldehyde, the Main Active Ingredient in Cinnamon, in the Treatment of Breast Cancer”, Frontiers in Pharmacology, 11, 2020.
  29. L. T. Ng and S.J. Wu, “Antiproliferative Activity of Cinnamomum cassia Constituents and Effects of Pifithrin‐Alpha on Their Apoptotic Signaling Pathways in Hep G2 Cells”, Evidence-Based Complementary and Alternative Medicine, 2011(1), 2011.
  30. C. M. Cabello, W. B. Bair, S. D. Lamore, S. Ley, A. S. Bause and S. Azimian, “The Cinnamon-Derived Michael Acceptor Cinnamic Aldehyde Impairs Melanoma Cell Proliferation, Invasiveness, and Tumor Growth”, Free Radical Biology and Medicine, 46(2), 220–231, 2009.
  31. K. H. Moon and M. Y. Pack, “Cytotoxicity of Cinnamic Aldehyde on Leukemia L1210 Cells”, Drug and Chemical Toxicology, 6(6), 521–535, 1983.
  32. C. Yu, S. L. Liu, M. H. Qi and X. Zou, “Cinnamaldehyde/Chemotherapeutic Agents Interaction and Drug-Metabolizing Genes in Colorectal Cancer”, Molecular Medicine Reports, 9(2), 669–676, 2014.
  33. M. Long, S. Tao, M. Rojo de la Vega, T. Jiang, Q. Wen, S. L. Park, D. D. Zhang and G. T. Wondrak. “Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. Cancer Prevention Research (Phila), 8(5), 444–454, 2015
  34. J. Park and S. H. Baek. “Combination Therapy with Cinnamaldehyde and Hyperthermia Induces Apoptosis of A549 Non-Small Cell Lung Carcinoma Cells via Regulation of Reactive Oxygen Species and Mitogen-Activated Protein Kinase Family.” International Journal of Molecular Sciences, 21(17), 6229, 2020.
  35. R. Chen, J. Wu, C. Lu, T. Yan, Y. Qian, H. Shen, Y. Zhao, J. Wang, P. Kong and X. Zhang, “Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer.” Frontiers in Pharmacology, 11, 2021.
  36. S. Mulati, F. Shen, Z. Talihati, Y. Zhang, H. Huang and W. Zhang, “Targeting RPS16 with Cinnamaldehyde to Suppress Cervical Cancer: Inhibition of the PI3K/AKT Pathway and Degradation of HPV E6 and E7 Proteins”, Biochemical Pharmacology, 242, 117225, 2025.
  37. J. Mei, J. Ma, Y. Xu, Y. Wang, M. Hu, F. Ma, Z. Qin, R. Xue, and N. Tao “Cinnamaldehyde Treatment of Prostate Cancer-Associated Fibroblasts Prevents Their Inhibitory Effect on T Cells Through Toll-Like Receptor 4.” Drug Design, Development and Therapy, 14, 3363-3372, 2020.
  38. L. Han, J. Mei, J. Ma, F. Wang, Z. Gu, J. Li, Z. Zhang, Y. Zeng, X. Lou, X. Yao, N. Tao and Z. Qin, “Cinnamaldehyde induces endogenous apoptosis of the prostate cancer-associated fibroblasts via interfering the Glutathione-associated mitochondria function.” Medical Oncology, 37(10), 91, 2020.
  39. A. N. Aliyah, G. Lintangsari, G. G. Maran, A. Hermawan and E. Meiyanto, “Cinnamon Oil as a Co-Chemotherapy Agent Through Inhibition of Cell Migration and MMP-9 Expression on 4T1 Cells”, Journal of Complementary and Integrative Medicine, 19(4), 921–928, 2022.
  40. C. Wu en, Y. wen Zhuang, Y. yong Zhou, S. lin Liu, R. ping Wang and P. Shu, “Cinnamaldehyde Enhances Apoptotic Effect of Oxaliplatin and Reverses Epithelial-Mesenchymal Transition and Stemness in Hypoxic Colorectal Cancer Cells”, Experimental Cell Research, 383(1), 111500, 2019.
  41. C. Wu, Y. Zhuang, S. Jiang, F. Tian, Y. Teng and X. Chen, “Cinnamaldehyde Induces Apoptosis and Reverses Epithelial-Mesenchymal Transition Through Inhibition of Wnt/β-Catenin Pathway in Non-Small Cell Lung Cancer”, International Journal of Biochemistry and Cell Biology, 84, 58–74, 2017.